Media Centre

Our drug screening device is currently in development.
Sign up to our newsletter for regular updates.

New Chairman appointed to spearhead the launch of biometric drug screening technology

8 June 2015 - Philip Hand, a drug industry veteran with more than 20 years’ experience in medical diagnostics, has been appointed Chairman at Intelligent Fingerprinting, the British company developing the world’s first fingerprint-based drug screening device.  Mr Hand was previously a non-executive director at the company.


Philip Hand is known for his success in bringing diagnostic screening products to market.  He co-founded the medical diagnostics company Cozart Bioscience Limited which pioneered the development and manufacture of oral fluid (saliva) testing for drug screening.  Following the company’s AIM listing in 2004 he was its Chief Operating Officer until October 2007 when he was involved in the negotiation to sell the company to Concateno plc (now Alere Toxicology) for £65 million.


Read on or download full press release (pdf)...


John Polden, who has been the company’s Chairman since 2009, will remain on the Board as a non-executive director following Mr Hand’s appointment.


Dr Jerry Walker, Chief Executive Officer, Intelligent Fingerprinting said:  “The Board would like to thank John Polden for his excellent guidance and encouragement as Chairman over the past six years, during which time we have raised almost £6m in funding and won nearly £1m in grants and similar awards.  John has demonstrated that he is an expert in guiding start-ups onto the road to future success.  He was instrumental in securing all of the early stage funding for the company and his support has helped us bring an innovative concept to the point where we can now commercialise our revolutionary biometric drug screening technology, protected by a broad portfolio of intellectual property covering fingerprint-based diagnostics.”


Dr Walker continued: “Philip is a seasoned and highly successful business leader.  His in-depth knowledge of the drug screening industry and his experience of bringing diagnostic screening products to market mean that he is ideally positioned as Chairman to lead the company into the most exciting stage in its development – the launch and commercialisation phase of our ground-breaking technology.”


Mr Hand is a Business Ambassador for the Meningitis Now charity, a Fellow of the Chartered Institute of Management Accountants and a keen and active sportsman.




For media information contact Lorraine Walters at Say Communications
Email:  Tel: +44 (0)20 8971 6400